News
06-11-2008, 02:24 AM
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that a multicenter Phase 3 study of Lymphoseek® has been initiated in patients with either breast cancer or melanoma. The Phase 3 study will evaluate the efficacy of Lymphoseek to identify lymph nodes that may be predictive of determining whether a patient's cancer has spread into the lymphatic system.
More... (http://www.medicalnewstoday.com/articles/110659.php)
More... (http://www.medicalnewstoday.com/articles/110659.php)